Esperion Therapeutics, Inc. Announces Pricing of Initial Public Offering
June 26 2013 - 8:00AM
Business Wire
Esperion Therapeutics, Inc., a clinical-stage biopharmaceutical
company focused on developing and commercializing first-in-class,
oral, low-density lipoprotein cholesterol (LDL-C) lowering
therapies for the treatment of hypercholesterolemia, today
announced the pricing of its initial public offering of 5,000,000
shares of its common stock at a price to the public of $14.00 per
share. The shares are expected to begin trading on the NASDAQ
Global Market on June 26, 2013 under the symbol “ESPR.” In
addition, Esperion has granted the underwriters a 30-day option to
purchase up to an additional 750,000 shares of common stock to
cover over-allotments, if any.
Credit Suisse Securities (USA) LLC and Citigroup Global Markets
Inc. are acting as joint book-running managers for the offering.
JMP Securities LLC and Stifel, Nicolaus & Company, Incorporated
are acting as co-managers.
A registration statement relating to these securities was
declared effective by the Securities and Exchange Commission on
June 25, 2013. When available, copies of the final prospectus
relating to the offering may be obtained by contacting Credit
Suisse Securities (USA) LLC, Attention: Prospectus Department, One
Madison Avenue, New York, NY 10010, by calling toll-free (800)
221-1037, or by emailing newyork.prospectus@credit-suisse.com; or
Citigroup Global Markets Inc., c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, NY 11717, or by email at
batprospectusdept@citi.com, by phone at (800) 831-9146.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
Media Contact:BrewLifeDenise Powell,
510.703.9491dpowell@brewlife.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024